Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Offers 10 Million Shares at $7.10 Each

NEW YORK, June 20 - Exelixis said today that it will offer 10 million shares of its common stock at $7.10 per share.


The South San Francisco-based company expects to earn approximately $66.3 million in net proceeds from the offering. Underwriters will have the option to purchase up to an additional 1.5 million shares of common stock.


Exelixis' common stock was trading at about $7.30 this morning.


The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.